Compare PNBK & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNBK | MXCT |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.5M | 136.0M |
| IPO Year | 2006 | 2021 |
| Metric | PNBK | MXCT |
|---|---|---|
| Price | $1.09 | $1.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 1.0M | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.31 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.86 | $0.64 |
| 52 Week High | $2.00 | $2.37 |
| Indicator | PNBK | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 60.92 |
| Support Level | $0.88 | $0.77 |
| Resistance Level | $1.16 | $1.33 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 44.66 | 60.57 |
Patriot National Bancorp Inc provides consumer and commercial banking services to individuals, small and medium-sized businesses, professionals, and municipalities in Fairfield and New Haven Counties in Connecticut and Westchester County, New York. Its products include checking accounts, savings accounts, money market accounts, time certificates of deposit, and individual retirement accounts. The Bank's lending portfolio is comprised of commercial mortgage and construction loans, commercial loans, home improvement loans, home equity lines of credit, and other personal loans. In addition, the Bank offers bank checks, money orders, automated teller machines, interactive teller machines, online and mobile banking, credit cards, and debit cards.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.